Rose TL, Kim WY (2024) Renal cell carcinoma: a review. JAMA 332(12):1001–1010. https://doi.org/10.1001/jama.2024.12848

Article  CAS  PubMed  PubMed Central  Google Scholar 

van der Mijn JC, Al Hussein Al Awamlh B, Islam Khan A et al (2019) Validation of risk factors for recurrence of renal cell carcinoma: results from a large single-institution series. PLoS ONE 14(12):e0226285. https://doi.org/10.1371/journal.pone.0226285

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakajima N, Miyajima A, Shinohara N et al (2022) Risk factors for recurrence after operation in patients with pT1a renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association. Jpn J Clin Oncol 52(3):274–280. https://doi.org/10.1093/jjco/hyab201

Article  PubMed  Google Scholar 

Marconi L, Sun M, Beisland C et al (2021) Prevalence, disease-free, and overall survival of contemporary patients with renal cell carcinoma eligible for adjuvant checkpoint inhibitor trials. Clin Genitourin Cancer 19(2):e92–e99. https://doi.org/10.1016/j.clgc.2020.12.005

Article  PubMed  Google Scholar 

Ishiyama Y, Kondo T, Ishihara H et al (2022) C-reactive protein kinetics to predict recurrence of high-risk renal cell carcinoma after radical surgery. Int J Clin Oncol 27(5):969–976. https://doi.org/10.1007/s10147-022-02136-6

Article  CAS  PubMed  Google Scholar 

Choueiri TK, Tomczak P, Park SH et al (2021) Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med 385(8):683–694. https://doi.org/10.1056/NEJMoa2106391

Article  CAS  PubMed  Google Scholar 

Choueiri TK, Tomczak P, Park SH et al (2024) Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N Engl J Med 390(15):1359–1371. https://doi.org/10.1056/NEJMoa2312695

Article  CAS  PubMed  Google Scholar 

Powles T, Tomczak P, Park SH et al (2022) Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23(9):1133–1144. https://doi.org/10.1016/s1470-2045(22)00487-9

Article  CAS  PubMed  Google Scholar 

Leibovich BC, Blute ML, Cheville JC et al (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97(7):1663–1671. https://doi.org/10.1002/cncr.11234

Article  PubMed  Google Scholar 

Zisman A, Pantuck AJ, Dorey F et al (2001) Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19(6):1649–1657. https://doi.org/10.1200/jco.2001.19.6.1649

Article  CAS  PubMed  Google Scholar 

Frank I, Blute ML, Cheville JC et al (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168(6):2395–2400. https://doi.org/10.1016/s0022-5347(05)64153-5

Article  PubMed  Google Scholar 

Correa AF, Jegede O, Haas NB et al (2019) Predicting renal cancer recurrence: defining limitations of existing prognostic models with prospective trial-based validation. J Clin Oncol 37(23):2062–2071. https://doi.org/10.1200/jco.19.00107

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hirata H, Fujii N, Oka S et al (2024) C-reactive protein-albumin-lymphocyte index as a novel biomarker for progression in patients undergoing surgery for renal cancer. Cancer Diagn Progn 4(6):748–753. https://doi.org/10.21873/cdp.10391

Article  PubMed  PubMed Central  Google Scholar 

Peyton CC, Abel EJ, Chipollini J et al (2020) The value of neutrophil to lymphocyte ratio in patients undergoing cytoreductive nephrectomy with thrombectomy. Eur Urol Focus 6(1):104–111. https://doi.org/10.1016/j.euf.2018.08.023

Article  PubMed  Google Scholar 

Lai GS, Li JR, Wang SS et al (2022) Tumor size significantly affects prognosis in pathological T3a renal cell carcinoma. Anticancer Res 42(4):2185–2191. https://doi.org/10.21873/anticanres.15701

Article  CAS  PubMed  Google Scholar 

Siemer S, Lehmann J, Loch A et al (2005) Current TNM classification of renal cell carcinoma evaluated: revising stage T3a. J Urol 173(1):33–37. https://doi.org/10.1097/01.ju.0000146719.43269.e8

Article  CAS  PubMed  Google Scholar 

Lam JS, Klatte T, Patard JJ et al (2007) Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol 52(1):155–162. https://doi.org/10.1016/j.eururo.2007.01.106

Article  PubMed  Google Scholar 

Yoo C, Song C, Hong JH et al (2008) Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma. J Urol 180(2):486–491. https://doi.org/10.1016/j.juro.2008.04.034

Article  PubMed  Google Scholar 

Caetano SJ, Sonpavde G, Pond GR (2018) C-statistic: a brief explanation of its construction, interpretation and limitations. Eur J Cancer 90:130–132. https://doi.org/10.1016/j.ejca.2017.10.027

Article  CAS  PubMed  Google Scholar 

Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15(4):361–387. https://doi.org/10.1002/(sici)1097-0258(19960229)15:4%3c361::aid-sim168%3e3.0.co;2-4

Article  PubMed  Google Scholar 

Ohsugi H, Ohe C, Yoshida T et al (2021) Predictors of postoperative recurrence in patients with non-metastatic pT3a renal cell carcinoma. Int J Urol 28(10):1060–1066. https://doi.org/10.1111/iju.14648

Article  CAS  PubMed  Google Scholar 

Li X, Huang Q, Gu L et al (2024) Development and validation of a nomogram for predicting postoperative recurrence-free survival in patients with nonmetastatic pathological T3a stage renal cell carcinoma. Clin Genitourin Cancer 22(6):102196. https://doi.org/10.1016/j.clgc.2024.102196

Article  PubMed  Google Scholar 

Choi Y, Park B, Jeong BC et al (2013) Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. Int J Cancer 132(3):625–634. https://doi.org/10.1002/ijc.27639

Article  CAS  PubMed  Google Scholar 

Turco F, Tucci M, Di Stefano RF et al (2021) Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC. Endocr Relat Cancer 28(7):R207–R216. https://doi.org/10.1530/erc-20-0457

Article  PubMed  Google Scholar 

Graff RE, Wilson KM, Sanchez A et al (2022) Obesity in relation to renal cell carcinoma incidence and survival in three prospective studies. Eur Urol 82(3):247–251. https://doi.org/10.1016/j.eururo.2022.04.032

Article  CAS  PubMed  Google Scholar 

Chang Y, An H, Xu L et al (2015) Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma. Br J Cancer 113(4):626–633. https://doi.org/10.1038/bjc.2015.241

Article  CAS  PubMed  PubMed Central